Literature DB >> 25867649

JC polyomavirus reactivation is common following allogeneic stem cell transplantation and its preemptive detection may prevent lethal complications.

T Wittmann1, N Horowitz2, N Benyamini3, I Henig3, T Zuckerman2, J M Rowe4, Z Kra-Oz5, M Szwarcwort Cohen6, I Oren7, I Avivi8.   

Abstract

Extended application of allogeneic stem cell transplantation (alloSCT) is expected to increase the frequency of JC polyomavirus (JCPyV)-related progressive multifocal leukoencephalopathy (PML). The aim of this study was to assess frequency, risk factors and course of JCPyV reactivation in allografted hematology patients. This retrospective study included consecutive adult patients, treated with alloSCT between January 2008 and December 2011. Quantitative JCPyV-PCR analysis was performed on whole blood DNA samples, originally drawn for cytomegalovirus detection since transplant date. The study included 164 patients diagnosed with hematological malignancies. Patients received reduced-intensity conditioning (n=74) or myeloablative conditioning (n=90), followed by alloSCT. Twenty patients developed transient and 20 had persistent JCPyV reactivation. Two of the patients with persistent reactivation showed a gradual increase in JCPyV levels, preceding PML development by 96 and 127 days. Cessation of immunosuppression resulted in complete resolution of neurological symptoms in one patient, while the other died of PML. Seventy percent of the 'persistently reactivating' patients died. Multivariate analysis confirmed age to be the only significant predictive factor for JCPyV reactivation. In conclusion, JCPyV reactivation occurs in a quarter of allografted patients. Preemptive detection of JCPyV reactivation in high-risk subjects and early discontinuation of immunosuppressive therapy may prevent development of lethal PML.

Entities:  

Mesh:

Year:  2015        PMID: 25867649     DOI: 10.1038/bmt.2015.68

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  37 in total

Review 1.  Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature.

Authors:  M A Kharfan-Dabaja; E Ayala; J Greene; A Rojiani; F R Murtagh; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2006-12-04       Impact factor: 5.483

Review 2.  Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.

Authors:  Leonard H Calabrese; Eamonn S Molloy; DeRen Huang; Richard M Ransohoff
Journal:  Arthritis Rheum       Date:  2007-07

Review 3.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

4.  The EBMT activity survey 2009: trends over the past 5 years.

Authors:  H Baldomero; M Gratwohl; A Gratwohl; A Tichelli; D Niederwieser; A Madrigal; K Frauendorfer
Journal:  Bone Marrow Transplant       Date:  2011-02-28       Impact factor: 5.483

Review 5.  The clinical features of PML.

Authors:  Joseph R Berger
Journal:  Cleve Clin J Med       Date:  2011-11       Impact factor: 2.321

Review 6.  Pathogenesis of progressive multifocal leukoencephalopathy--revisited.

Authors:  Martyn K White; Kamel Khalili
Journal:  J Infect Dis       Date:  2011-01-12       Impact factor: 5.226

7.  JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals.

Authors:  Raphael P Viscidi; Nina Khanna; Chen S Tan; Xiuhung Li; Lisa Jacobson; David B Clifford; Avindra Nath; Joseph B Margolick; Keerti V Shah; Hans H Hirsch; Igor J Koralnik
Journal:  Clin Infect Dis       Date:  2011-08-18       Impact factor: 9.079

8.  Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.

Authors:  S Morecki; Y Gelfand; A Nagler; R Or; E Naparstek; G Varadi; D Engelhard; A Akerstein; S Slavin
Journal:  Bone Marrow Transplant       Date:  2001-08       Impact factor: 5.483

Review 9.  Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.

Authors:  Mohamed L Sorror; Frederick R Appelbaum
Journal:  Expert Rev Hematol       Date:  2013-10-02       Impact factor: 2.929

Review 10.  New insights into progressive multifocal leukoencephalopathy.

Authors:  Igor J Koralnik
Journal:  Curr Opin Neurol       Date:  2004-06       Impact factor: 5.710

View more
  4 in total

Review 1.  Beyond Cytomegalovirus and Epstein-Barr Virus: a Review of Viruses Composing the Blood Virome of Solid Organ Transplant and Hematopoietic Stem Cell Transplant Recipients.

Authors:  Marie-Céline Zanella; Samuel Cordey; Laurent Kaiser
Journal:  Clin Microbiol Rev       Date:  2020-08-26       Impact factor: 26.132

2.  JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.

Authors:  Elena Uleri; Gabriele Ibba; Claudia Piu; Maurizio Caocci; Stefania Leoni; Giannina Arru; Caterina Serra; GianPietro Sechi; Antonina Dolei
Journal:  J Neurovirol       Date:  2016-11-03       Impact factor: 2.643

3.  Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host disease.

Authors:  L Kaiser; D L Vu; M C Zanella; S Cordey; F Laubscher; M Docquier; G Vieille; C Van Delden; V Braunersreuther; Mc Kee Ta; J A Lobrinus; S Masouridi-Levrat; Y Chalandon
Journal:  Microbiome       Date:  2021-01-24       Impact factor: 14.650

4.  Progressive multifocal leukoencephalopathy as the first presentation of sarcoidosis.

Authors:  Maha Elbadri; Gordon Plant
Journal:  BMJ Case Rep       Date:  2020-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.